Opipza is a drug owned by Xiamen Lp Pharmacuetical Co Ltd. It is protected by 2 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 15, 2041. Details of Opipza's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11701352 | Process for preparing aripiprazole oral soluble film |
Dec, 2041
(16 years from now) | Active |
| US11331315 | Aripiprazole oral soluble film |
Nov, 2040
(15 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Opipza is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Opipza's family patents as well as insights into ongoing legal events on those patents.
Opipza's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Opipza:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Opipza(Aripiprazole) has 2 clinical trials that have been verified in 2024. Out of these 2, 1 trial is in PHASE4.
Generic Launch
Generic Release Date:
Opipza's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 15, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Opipza Generic API suppliers:
Aripiprazole is the generic name for the brand Opipza. 28 different companies have already filed for the generic of Opipza, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Opipza's generic
Alternative Brands for Opipza
There are several other brand drugs using the same active ingredient (Aripiprazole) as Opipza. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Alkermes Inc |
| |||
| Cmg Pharm Co Ltd |
| |||
| Otsuka |
| |||
| Otsuka Pharm Co Ltd |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Aripiprazole, Opipza's active ingredient. Check the complete list of approved generic manufacturers for Opipza
About Opipza
Opipza is a drug owned by Xiamen Lp Pharmacuetical Co Ltd. Opipza uses Aripiprazole as an active ingredient. Opipza was launched by Xiamen Lp Pharm Co in 2024.
Approval Date:
Opipza was approved by FDA for market use on 22 July, 2024.
Active Ingredient:
Opipza uses Aripiprazole as the active ingredient. Check out other Drugs and Companies using Aripiprazole ingredient
Dosage:
Opipza is available in film form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG | FILM | Prescription | ORAL |
| 10MG | FILM | Prescription | ORAL |
| 5MG | FILM | Prescription | ORAL |